Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma.
choriocarcinoma
gestational trophoblastic disease
gestational trophoblastic neoplasia
hydatidiform mole
placenta
transforming growth factor beta
trophoblast
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
14 Oct 2021
14 Oct 2021
Historique:
received:
31
08
2021
revised:
01
10
2021
accepted:
08
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
The human placenta shares properties with solid tumors, such as rapid growth, tissue invasion, cell migration, angiogenesis, and immune evasion. However, the mechanisms that drive the evolution from premalignant proliferative placental diseases-called hydatidiform moles-to their malignant counterparts, gestational choriocarcinoma, as well as the factors underlying the increased aggressiveness of choriocarcinoma arising after term delivery compared to those developing from hydatidiform moles, are unknown. Using a 730-gene panel covering 13 cancer-associated canonical pathways, we compared the transcriptomic profiles of complete moles to those of postmolar choriocarcinoma samples and those of postmolar to post-term delivery choriocarcinoma. We identified 33 genes differentially expressed between complete moles and postmolar choriocarcinoma, which revealed TGF-β pathway dysregulation. We found the strong expression of SALL4, an upstream regulator of TGF-β, in postmolar choriocarcinoma, compared to moles, in which its expression was almost null. Finally, there were no differentially expressed genes between postmolar and post-term delivery choriocarcinoma samples. To conclude, the TGF-β pathway appears to be a crucial step in the progression of placental malignancies. Further studies should investigate the value of TGF- β family members as biomarkers and new therapeutic targets.
Identifiants
pubmed: 34680590
pii: biomedicines9101474
doi: 10.3390/biomedicines9101474
pmc: PMC8533618
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cancer. 2017 Jul 5;8(11):2033-2041
pubmed: 28819404
Exp Cell Res. 1994 Sep;214(1):93-9
pubmed: 8082752
Eur J Cancer. 2015 Sep;51(13):1725-31
pubmed: 26092638
Open Biol. 2018 Jun;8(6):
pubmed: 29950452
J Obstet Gynaecol India. 2014 Dec;64(Suppl 1):29-31
pubmed: 25404801
J Transl Med. 2018 Jul 9;16(1):191
pubmed: 29986714
Br J Cancer. 2006 Nov 6;95(9):1145-7
pubmed: 17031399
Cancer Manag Res. 2018 Oct 10;10:4459-4470
pubmed: 30349378
Int J Gynaecol Obstet. 2002 Jun;77(3):285-7
pubmed: 12065144
Gynecol Oncol. 2020 Sep;158(3):785-793
pubmed: 32513563
BJOG. 2020 Aug;127(9):1102-1107
pubmed: 32146729
Am J Obstet Gynecol. 2021 Apr;224(4):372.e1-372.e30
pubmed: 33031755
Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:29-41
pubmed: 33685819
Histol Histopathol. 2007 Mar;22(3):227-34
pubmed: 17163397
Clin Ther. 2021 Feb;43(2):246-264
pubmed: 33446335
Am J Obstet Gynecol. 2016 Mar;214(3):390.e1-8
pubmed: 26433171
Signal Transduct Target Ther. 2020 Jun 30;5(1):110
pubmed: 32606334
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):
pubmed: 28246180
Cancers (Basel). 2021 Jun 15;13(12):
pubmed: 34203890
J Gynecol Obstet Biol Reprod (Paris). 2016 Jun;45(6):559-62
pubmed: 26323857
Hum Pathol. 2016 Aug;54:121-6
pubmed: 27068524
J Biochem Mol Toxicol. 2019 Mar;33(3):e22262
pubmed: 30431698
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1097-101
pubmed: 18021220
Mol Cancer. 2018 Dec 20;17(1):176
pubmed: 30572883
Oncotarget. 2016 Nov 22;7(47):78206-78218
pubmed: 27661009
Nature. 2021 Apr;592(7852):80-85
pubmed: 33692543
Am J Hum Genet. 2018 Nov 1;103(5):740-751
pubmed: 30388401